

GLAXOSMITHKLINE PLC

Form 6-K

October 02, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending October 2012

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.

On 28 September 2012, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £14.37 per Ordinary Share, and notional ADSs at a price of \$46.52 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2012 to 30 September 2012:

Non Executive Director	Ordinary Shares	American Depositary Shares (ADSs)
Sir Christopher Gent	2,348.643	
Professor Sir Roy Anderson	456.681	
Dr Stephanie Burns		443.463
Stacey Cartwright	326.200	
Sir Crispin Davis	1,652.749	
Lynn Elsenhans		570.166
Judy Lewent		221.731
Sir Deryck Maughan		886.925
Dr Daniel Podolsky		855.249
Tom de Swaan	674.148	
Jing Ulrich		158.379
Sir Robert Wilson	456.681	

The Company and the Non-Executive Directors were informed of these allocations on 1 October 2012.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte
Company Secretary
2 October 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: October 02, 2012

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc